Treating iPSC-Derived β Cells with an Anti-CD30 Antibody–Drug Conjugate Eliminates the Risk of Teratoma Development upon Transplantation

Insulin-producing cells derived from induced pluripotent stem cells (iPSCs) are promising candidates for β cell replacement in type 1 diabetes. However, the risk of teratoma formation due to residual undifferentiated iPSCs contaminating the differentiated cells is still a critical concern for clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellegrini, Silvia, Zamarian, Valentina, Landi, Elisa, Cospito, Alessandro, Lombardo, Marta Tiffany, Manenti, Fabio, Citro, Antonio, Schiavo Lena, Marco, Piemonti, Lorenzo, Sordi, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456216/
https://www.ncbi.nlm.nih.gov/pubmed/36077097
http://dx.doi.org/10.3390/ijms23179699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456216/
https://www.ncbi.nlm.nih.gov/pubmed/36077097
http://dx.doi.org/10.3390/ijms23179699

Ejemplares similares